Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Retisert: Phase III

An intent-to-treat analysis of 12-month follow-up data from a Phase III trial in 80 patients showed that 48.8% of patients that received the 0.5 mg Retisert insert had a

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE